Inhibikase Therapeutics, Inc. (IKT) Operating cash flow 2020–2025
Inhibikase Therapeutics, Inc. (IKT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$27.8MFY2025 · since FY2020: -$1.1M → -$27.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$27.8M | -45.1% |
| FY2024 | -$19.1M | -5.9% |
| FY2023 | -$18.1M | -4.2% |
| FY2022 | -$17.4M | -21.4% |
| FY2021 | -$14.3M | -1165.9% |
| FY2020 | -$1.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice